{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:07:38Z","timestamp":1788944858845,"version":"build-2803163510"},"reference-count":39,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Sci.","Medical Sciences"],"abstract":"<jats:p>Background: Nephrolithiasis frequently coexists with type 2 diabetes, obesity, gout, chronic kidney disease, and other cardiometabolic disorders. Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors may influence stone formation through effects on glucosuria, natriuresis, urine volume, urinary citrate, pH, urate handling, and relative supersaturation. This review aimed to examine the current mechanistic, biochemical, and clinical evidence linking SGLT2 inhibition to nephrolithiasis, with particular attention to its relevance for urological practice. Methods: A clinically oriented narrative review was conducted using PubMed\/MEDLINE, Scopus, Web of Science, and Google Scholar. The final search was performed on 1 July 2026. A total of 15 studies were included. Randomised trials, pooled and post hoc analyses, observational and comparative-effectiveness studies, meta-analyses, human mechanistic studies, and relevant experimental investigations were considered. Evidence was synthesised narratively according to biological mechanisms, urinary chemistry and relative supersaturation, randomised evidence, and observational clinical outcomes. Clinical stone events were analysed separately from surrogate urinary endpoints. Results: SGLT2 inhibition is associated with reproducible increases in urinary citrate and variable effects on urine volume, urinary pH, and the excretion of calcium, phosphate, and urate. Short-term mechanistic studies suggest reductions in calcium phosphate supersaturation and, in selected uric acid stone formers, uric acid supersaturation, whereas effects on calcium oxalate supersaturation remain inconsistent. Observational studies and secondary analyses of randomised trials generally indicate fewer nephrolithiasis events among SGLT2 inhibitor users; however, most outcomes were based on adverse-event reporting or administrative codes and lacked stone composition, standardised imaging, urinary phenotyping, and recurrence adjudication. Conclusions: SGLT2 inhibitors may favourably modify selected lithogenic pathways, but their effects appear phenotype-dependent and have not yet been shown to directly prevent stone recurrence. They should not be initiated solely for the prevention of nephrolithiasis. In patients with established cardiovascular, renal, or metabolic indications, their potential urinary effects may represent an additional benefit. Dedicated long-term randomised studies with stone-specific endpoints are required.<\/jats:p>","DOI":"10.3390\/medsci14050555","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:05:43Z","timestamp":1788941143000},"page":"555","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 Inhibitors in Nephrolithiasis: Emerging Evidence and What Urologists Need to Know"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4146-9131","authenticated-orcid":false,"given":"Marius","family":"Iv\u0103nu\u021b\u0103","sequence":"first","affiliation":[{"name":"Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania"},{"name":"Department of Urology, \u201cDr. C.I. Parhon\u201d Clinical Hospital, 700503 Iasi, Romania"},{"name":"Center for Morphological and Spectroscopic Analysis of Urinary Stones\u201d Michel Daudon\u201d, 700503 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3453-1251","authenticated-orcid":false,"given":"Drago\u0219","family":"Puia","sequence":"additional","affiliation":[{"name":"Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania"},{"name":"Department of Urology, \u201cDr. C.I. Parhon\u201d Clinical Hospital, 700503 Iasi, Romania"},{"name":"Center for Morphological and Spectroscopic Analysis of Urinary Stones\u201d Michel Daudon\u201d, 700503 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Iv\u0103nu\u021b\u0103","sequence":"additional","affiliation":[{"name":"Emergency Care Department, \u201cSf. Spiridon\u201d County University Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Haut\u0103","sequence":"additional","affiliation":[{"name":"Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania"},{"name":"Department of Urology, \u201cDr. C.I. Parhon\u201d Clinical Hospital, 700503 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionu\u021b","family":"Nistor","sequence":"additional","affiliation":[{"name":"Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania"},{"name":"Department of Nephrology, \u201cDr. C.I. Parhon\u201d Clinical Hospital, 700503 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u0103t\u0103lin","family":"Pricop","sequence":"additional","affiliation":[{"name":"Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania"},{"name":"Department of Urology, \u201cDr. C.I. Parhon\u201d Clinical Hospital, 700503 Iasi, Romania"},{"name":"Center for Morphological and Spectroscopic Analysis of Urinary Stones\u201d Michel Daudon\u201d, 700503 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","unstructured":"Skolarikos, A., Davis, N.F., Gambaro, G., Geraghty, R., Jung, H., Kamphuis, G.M., Lardas, M., Neisius, A., Pet\u0159\u00edk, A., and Somani, B. (2026). EAU Guidelines on Urolithiasis, EAU Guidelines Office. Available online: https:\/\/uroweb.org\/guidelines."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00240-023-01407-9","article-title":"Place of Extracorporeal Shockwave Lithotripsy in the Treatment of Urolithiasis in the Region of Gharb Chrarda Bni Hssen (Morocco)","volume":"51","author":"Chakit","year":"2023","journal-title":"Urolithiasis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ndt\/gfae179","article-title":"SGLT2 Inhibitors and Nephrolithiasis Risk: A Meta-Analysis","volume":"40","author":"Kanbay","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41591-024-03330-x","article-title":"Empagliflozin in Nondiabetic Individuals with Calcium and Uric Acid Kidney Stones: A Randomized Phase 2 Trial","volume":"31","author":"Anderegg","year":"2025","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Dika, \u017d., \u017divko, M., Kljaji\u0107, M., and Jelakovi\u0107, B. (2024). SGLT2 Inhibitors and Their Effect on Urolithiasis: Current Evidence and Future Directions. J. Clin. Med., 13.","DOI":"10.3390\/jcm13196017"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.bbadis.2016.02.004","article-title":"Effects of Alanine: Glyoxylate Aminotransferase Variants and Pyridoxine Sensitivity on Oxalate Metabolism in a Cell-Based Cytotoxicity Assay","volume":"1862","author":"Fargue","year":"2016","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00240-026-02009-x","article-title":"Metabolic Origins of Hyperoxaluria: The Critical Role of Precursors and Vitamin B6 Status in Rats","volume":"54","author":"Ogawa","year":"2026","journal-title":"Urolithiasis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/MNH.0000000000000632","article-title":"Tubular Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Intended and Unintended Consequences","volume":"29","author":"Xue","year":"2020","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e059073","DOI":"10.1136\/bmjopen-2021-059073","article-title":"Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers (SWEETSTONE Trial): Protocol for a Randomised, Double-Blind, Placebo-Controlled Cross-over Trial","volume":"12","author":"Schietzel","year":"2022","journal-title":"BMJ Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106524","DOI":"10.1016\/j.phrs.2022.106524","article-title":"Inhibition of Sodium-Glucose Cotransporter 2 Suppresses Renal Stone Formation","volume":"186","author":"Anan","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_11","first-page":"282","article-title":"SGLT-2 Inhibitors and Their Correlation with Kidney Stones. A Systematic Review","volume":"4","author":"Alshehri","year":"2024","journal-title":"J. Health Rehabil. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"E3003","DOI":"10.1210\/clinem\/dgac154","article-title":"Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?","volume":"107","author":"Balasubramanian","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e080035","DOI":"10.1136\/bmj-2024-080035","article-title":"Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis among Patients with Pre-Existing Nephrolithiasis or Gout: Target Trial Emulation Studies","volume":"387","author":"McCormick","year":"2024","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1146\/annurev-med-043024-014508","article-title":"Nephrolithiasis: A Paleolithic Perspective and Physiological Approach to Prevention","volume":"77","author":"Ganesan","year":"2026","journal-title":"Annu. Rev. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dom.12439","article-title":"Effect of Canagliflozin on Serum Uric Acid in Patients with Type 2 Diabetes Mellitus","volume":"17","author":"Davies","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4081\/aiua.2015.2.105","article-title":"Dietary Treatment of Urinary Risk Factors for Renal Stone Formation. A Review of CLU Working Group","volume":"87","author":"Prezioso","year":"2015","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2021111515","article-title":"Empagliflozin Changes Urine Supersaturation by Decreasing PH and Increasing Citrate","volume":"33","author":"Harmacek","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e70594","DOI":"10.1111\/cts.70594","article-title":"Genetics of Response to Canagliflozin (GRC) Study: Rationale, Design, and Pharmacodynamic Responses","volume":"19","author":"Montasser","year":"2026","journal-title":"Clin. Transl. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lv, F., Zhang, D., Xu, C., and Xu, X. (2026). Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Uric Acid in Patients with Heart Failure and Preserved Ejection Fraction: A Retrospective Analysis in Real Word. BMC Cardiovasc. Disord., 26.","DOI":"10.1186\/s12872-026-05627-w"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107808","DOI":"10.1016\/j.diabres.2019.107808","article-title":"Nephrolithiasis and Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors: A Meta-Analysis of Randomized Controlled Trials","volume":"155","author":"Cosentino","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00125-021-05424-4","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nephrolithiasis","volume":"64","author":"Kristensen","year":"2021","journal-title":"Diabetologia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112088","DOI":"10.1016\/j.diabres.2025.112088","article-title":"SGLT2 Inhibitors and Nephrolithiasis Risk in Patients with Type 2 Diabetes: A Cohort Study and Meta-Analysis","volume":"222","author":"Yeh","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/cpt.3626","article-title":"Use of Sodium-Glucose Transport Protein 2 Inhibitors and the Incidence of Urolithiasis: A Multi-Database and Cross-Country Study in Patients with Type 2 Diabetes Mellitus","volume":"117","author":"Chung","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.34067\/KID.0000000981","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors Prevent Nephrolithiasis in Patients with Diabetes","volume":"7","author":"Liu","year":"2025","journal-title":"Kidney360"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5049\/EBP.2025.23.e5","article-title":"Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors for Uricosuria","volume":"23","author":"Bae","year":"2025","journal-title":"Electrolytes Blood Press."},{"key":"ref_26","first-page":"e20230146","article-title":"Sodium-Glucose Cotranspor Ter 2 (SGLT2) Inhibitors in Nephrolithiasis: Should We \u201cGliflozin\u201d Patients with Kidney Stone Disease?","volume":"46","year":"2024","journal-title":"J. Bras. Nefrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc24-1652","article-title":"Risk of Nephrolithiasis Associated with SGLT2 Inhibitors Versus DPP4 Inhibitors Among Patients with Type 2 Diabetes: A Target Trial Emulation Study","volume":"48","author":"Shin","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1536\/ihj.22-441","article-title":"Safety of SGLT2 Inhibitors in Three Chronic Diseases A Meta-Analysis Focusing on the Number Needed to Treat","volume":"64","author":"Ge","year":"2023","journal-title":"Int. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.15190\/d.2022.11","article-title":"Sodium Glucose Co-Transport 2 Inhibitors for Gout Treatment","volume":"10","author":"Somagutta","year":"2022","journal-title":"Discoveries"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3892\/etm.2022.11651","article-title":"Active Metabolic Lithiasis: A Condition That Requires Proper Evaluation and Monitoring","volume":"24","author":"Pricop","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00228-026-04023-9","article-title":"Beyond Safety: Adverse Events and Unanticipated Advantages of SGLT2 Inhibitors","volume":"82","author":"Falsetti","year":"2026","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Omi\u0107, H., Eder, M., Herkner, H., Seitz, C., Kiki\u0107, \u017d., and Schrag, T.A. (2025). Study Protocol for a Randomized Single-Center Cross-over Study: Dapagliflozin Treatment in Recurring Kidney Stone Patients. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0322034"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1038\/s41598-019-49525-y","article-title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"9","author":"Bae","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101690","DOI":"10.1016\/j.xcrm.2024.101690","article-title":"The SGLT2 Inhibitor Dapagliflozin Ameliorates Renal Fibrosis in Hyperuricemic Nephropathy","volume":"5","author":"Hu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ekir.2023.01.034","article-title":"Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis","volume":"8","author":"Anan","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/15548627.2024.2410621","article-title":"Empagliflozin Protects the Kidney by Reducing Toxic ALB (Albumin) Exposure and Preventing Autophagic Stagnation in Proximal Tubules","volume":"21","author":"Matsui","year":"2025","journal-title":"Autophagy"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Pricop, C., Iv\u0103nu\u021b\u0103, M., Nikolic, M., and Puia, D. (2024). Kidney Stones of Type I vs. Type II Diabetic Patients: Are There Any Differences?. J. Clin. Med., 13.","DOI":"10.3390\/jcm13206110"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","article-title":"Efficacy and Safety of Dapagliflozin According to Frailty in Patients with Heart Failure: A Prespecified Analysis of the DELIVER Trial","volume":"146","author":"Butt","year":"2022","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"glad181","DOI":"10.1093\/gerona\/glad181","article-title":"Efficacy and Safety of Dapagliflozin in Patients with Chronic Kidney Disease Across the Spectrum of Frailty","volume":"79","author":"Vart","year":"2024","journal-title":"J. Gerontol.-Ser. A Biol. Sci. Med. Sci."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/5\/555\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:27:10Z","timestamp":1788942430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/5\/555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medsci14050555"],"URL":"https:\/\/doi.org\/10.3390\/medsci14050555","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}